Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials

American Heart Journal

Volumn 152, Issue 1, 2006, Pages 27-38

  Stettler, Christoph ^a   Allemann, Sabin ^a   Jüni, Peter ^a,b   Cull, Carole A ^c   Holman, Rury R ^c   Egger, Matthias ^a,b   Krähenbühl, Stephan ^d   Diem, Peter ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ARTERY DISEASE; BLOOD GLUCOSE MONITORING; BLOOD VESSEL DIAMETER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; DATA ANALYSIS; DISEASE DURATION; GLYCEMIC CONTROL; GROUPS BY AGE; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; CEREBROVASCULAR ACCIDENT; COMORBIDITY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INCIDENCE; MALE; PERIPHERAL VASCULAR DISEASES; POSTPRANDIAL PERIOD; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33745661675     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.09.015     Document Type: Review

References (43)

1. Haffner S.J., and Cassells H. Hyperglycemia as a cardiovascular risk factor. Am J Med 115 Suppl 8A (2003) 6S-11S
2. Libby P., and Plutzky J. Diabetic macrovascular disease: the glucose paradox?. Circulation 106 (2002) 2760-2763
3. Deckert T., Poulsen J.E., and Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 14 (1978) 363-370
4. Morrish N.J., Stevens L.K., Head J., et al. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates. Diabetologia 33 (1990) 538-541
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329 (1993) 977-986
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 837-853
7. Feldt-Rasmussen B., Mathiesen E.R., Jensen T., et al. Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34 (1991) 164-170
8. Reichard P., and Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 43 (1994) 313-317
9. Shichiri M., Kishikawa H., Ohkubo Y., et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2 (2000) B21-B29
10. Verrillo A., de Teresa A., Martino C., et al. Long-term correction of hyperglycemia and progression of retinopathy in insulin dependent diabetes. A five-year randomized prospective study. Diabetes Res 8 (1988) 71-76
11. Holman R.R., Dornan T.L., Mayon-White V., et al. Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients. A two-year randomised prospective study. Lancet 1 (1983) 204-208
12. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. Microalbuminuria Collaborative Study Group, United Kingdom. BMJ 311 (1995) 973-977
13. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75 (1995) 894-903
14. Egger M., and Davey Smith G. Meta-analysis: potentials and promise. BMJ 315 (1997) 1371-1374
15. Robinson K.A., and Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol 31 (2002) 150-153
16. Juni P., Altman D.G., and Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 323 (2001) 42-46
17. Higgins J.P., and Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002) 1539-1558
18. Altman D.G. Confidence intervals for the number needed to treat. BMJ 317 (1998) 1309-1312
19. Egger M., Davey Smith G., and Minder C. Bias in meta-analysis detected by a simple, graphical test-authors reply. BMJ 316 (1998) 470-471
20. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997) 629-634
21. Thompson S.G., and Sharp S.J. Explaining heterogeneity in meta-analysis: a comparison of methods. Stat Med 18 (1999) 2693-2708
22. Abraira C., Colwell J., Nuttall F., et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 157 (1997) 181-188
23. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998) 854-865
24. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. Diabetologia 34 (1991) 877-890
25. Huang E.S., Meigs J.B., and Singer D.E. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111 (2001) 633-642
26. Lawson M.L., Gerstein H.C., Tsui E., et al. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. Diabetes Care 22 Suppl 2 (1999) B35-B39
27. Bartlett C., Davey P., Dieppe P., et al. Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001. Heart 89 (2003) 327-328
28. Selvin E., Marinopoulos S., Berkenblit G., et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141 (2004) 421-431
29. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317 (1998) 703-713
30. Malmberg K., Ryden L., Efendic S., et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 26 (1995) 57-65
31. Malmberg K., Ryden L., Wedel H., et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 26 (2005) 650-661
32. Svensson A.M., McGuire D.K., Abrahamsson P., et al. Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. Eur Heart J 26 (2005) 1255-1261
33. Beckman J.A., Creager M.A., and Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287 (2002) 2570-2581
34. Gaede P., Vedel P., Larsen N., et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 (2003) 383-393
35. Tan M.H., Johns D., Strand J., et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with type 2 diabetes. Diabet Med 21 (2004) 859-866
36. Nesto R. C-reactive protein, its role in inflammation, type 2 diabetes and cardiovascular disease, and the effects of insulin-sensitizing treatment with thiazolidinediones. Diabet Med 21 (2004) 810-817
37. Dunn C.J., and Peters D.H. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49 (1995) 721-749
38. Giugliano D., De Rosa N., Di Maro G., et al. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women. Diabetes Care 16 (1993) 1387-1390
39. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15 (1992) 1835-1843
40. Baynes J.W. Role of oxidative stress in development of complications in diabetes. Diabetes 40 (1991) 405-412
41. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis Of Diagnostic criteria in Europe. Lancet 354 (1999) 617-621
42. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290 (2003) 486-494
43. Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, (http://www.accordtrial.org/public/index.cfm), accessed August 22, 2005.